

LETTER



Epigenome-wide association study for 28-day survival of acute respiratory distress syndrome

Yichen Guo^{1,2}, Ruyang Zhang^{1,3}, Zhaozhong Zhu^{1,4}, Sipeng Shen^{1,3}, Li Su¹ and David C. Christiani^{1,4,5*}

© 2018 Springer-Verlag GmbH Germany, part of Springer Nature and ESICM

Dear Editor,

Acute respiratory distress syndrome (ARDS) is a severe lung disease with a mortality rate of over 40% among moderate-to-severe patients. A recent study demonstrated an association of microRNA (miRNA), an epigenetic regulator, with ARDS mortality [1]. Another epigenetic biomarker, DNA methylation, is associated with several inflammatory and pulmonary diseases [2]. DNA methylation, as a reversible epigenetic modification, offers potential diagnostic/prognostic and therapeutic value [2].

We conducted an epigenome-wide association study (EWAS) between DNA methylation and 28-day survival time in 185 moderate-to-severe ARDS patients from intensive care units (ICUs) (Table 1). DNA was extracted from whole blood, and methylation levels were measured on over 480,000 CpG sites. Associations between methylation and survival were evaluated by Cox models in two phases (discovery and validation) with adjustment for age, gender, APACHE III score, and cell-type heterogeneity. Results were described as hazard ratio (HR) and 95% confidence interval (95% CI) per 0.01-unit increment of methylation beta values. Multiple testing corrections were performed using false discovery rate (FDR). Details are provided in the Supplementary Methods.

We identified four CpG sites that were significantly associated with ARDS survival in both discovery and

validation phases (FDR < 0.05) (Supplementary Table 1). Two sites are related to inflammation and infection, which are common manifestations in ARDS. Site cg08504659 (discovery phase: HR = 1.34, $P = 7.53 \times 10^{-6}$; validation phase: HR = 1.22, $P = 1.58 \times 10^{-4}$) is located within *PTGDR* (encoding prostaglandin D2 receptor), which is a mediator of allergic inflammation and is recognized as a drug target of asthma [3]. Another site, cg04740513 (discovery phase: HR = 0.97, $P = 1.23 \times 10^{-5}$; validation phase: HR = 0.98, $P = 1.06 \times 10^{-4}$), is located within *ATP11A* (encoding integral membrane ATPase), which is associated with pulmonary disorders related to inflammation and fibrosis [4] and was recently identified as a novel element of the innate immune response and inflammatory response [5].

By integrating all four statistically significant methylation sites, we built a methylation risk score for each patient (Supplementary Methods). Patients with a higher methylation risk score had a significantly higher hazard of death within 28 days (HR = 1.72 per 1-unit increment, $P = 2.73 \times 10^{-7}$); the mortality HR was comparable to that of APACHE III score (HR = 1.71 per 40-unit increment, $P = 5.00 \times 10^{-4}$) (Supplementary Table 2). Similarly, the area under the receiver operating characteristic (ROC) curve (AUC) for prediction of 28-day ARDS mortality was comparable between methylation risk score (0.68) and APACHE III score (0.67) (Supplementary Fig. 1).

*Correspondence: dchris@hsph.harvard.edu

⁵ Pulmonary and Critical Care Division, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA

Full author information is available at the end of the article

Table 1 Baseline demographic characteristics of ARDS patients

	Discovery phase	Validation phase
<i>N</i>	92	93
Female, <i>n</i> (%)	21 (22.8)	44 (47.3)
Age, median years (range)	65 (22–87)	69 (22–97)
Baseline severity of illness (1st 24 h of ICU admission)		
APACHE III, median (range)	83 (26–135)	96 (41–150)
PaO ₂ /FiO ₂ , median (range)	108 (34–193)	103 (37–200)
100 ≤ PaO ₂ /FiO ₂ ≤ 200, <i>n</i> (%)	53 (57.6)	50 (53.8)
PaO ₂ /FiO ₂ < 100, <i>n</i> (%)	39 (42.4)	43 (46.2)
Systolic blood pressure, < 90 mmHg, <i>n</i> (%)	66 (71.7)	76 (81.7)
Heart rate, > 100 beats/min, <i>n</i> (%)	70 (76.1)	73 (78.5)
Respiratory rate, > 30 breaths/min, <i>n</i> (%)	50 (54.3)	40 (43.0)
Comorbidities		
Diabetes, <i>n</i> (%)	23 (25.0)	18 (19.4)
Predisposing conditions for ARDS		
Sepsis syndrome, <i>n</i> (%)	86 (93.5)	82 (88.2)
Septic shock, <i>n</i> (%)	77 (83.7)	77 (82.8)
Pneumonia, <i>n</i> (%)	25 (27.2)	35 (37.6)
Trauma, <i>n</i> (%)	1 (1.1)	1 (1.1)
Lung contusion, <i>n</i> (%)	2 (2.2)	1 (1.1)
Cancer		
Solid tumor, <i>n</i> (%)	3 (3.4)	5 (5.4)
Leukemia, <i>n</i> (%)	0	0
Non-Hodgkin's lymphoma, <i>n</i> (%)	0	2 (2.2)
Survival profiles		
28-day death, <i>n</i> (%)	60 (65.2)	85 (91.4)
Median survival days	14	10

We acknowledge some limitations of this study. First, although the two cohorts were recruited at different periods and measured separately (Supplementary Methods), all patients were recruited from two hospitals in the Boston area, which may limit generalizability. Second, all patients were moderate-to-severe cases recruited in the early years of our study, during a time in which high in-hospital mortality was common. However, our sensitivity analysis showed that the findings are consistent in subpopulations with lower mortality (Supplementary Methods, Supplementary Table 3).

To our knowledge, this is the first genome-wide epigenetic study among ARDS patients. While the sample size is limited, the discovered methylation sites showed putative biological importance, which highlights the feasibility of future large studies on DNA methylation in ARDS. In addition, the methylation risk score may ultimately be clinically useful for ARDS prognostic indication.

Electronic supplementary material

The online version of this article (<https://doi.org/10.1007/s00134-018-5100-5>) contains supplementary material, which is available to authorized users.

Author details

¹ Department of Environmental Health, Harvard T.H. Chan School of Public Health, Boston, MA, USA. ² Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA. ³ Department of Biostatistics, Ministry of Education Key Laboratory for Modern Toxicology, School of Public Health, Nanjing Medical University, Nanjing, China. ⁴ Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA. ⁵ Pulmonary and Critical Care Division, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.

Compliance with ethical standards

Conflicts of interest

The authors declare that they have no conflict of interest.

Ethical approval

The institutional review boards of the Massachusetts General Hospital, Beth Israel Deaconess Medical Center, and Harvard T.H. Chan School of Public Health approved this study.

Received: 9 January 2018 Accepted: 15 February 2018
Published online: 6 March 2018

References

1. Zhu Z, Zhang R, Liang L, Su L, Lu Q, Baccarelli AA, Bajwa EK, Thompson BT, Christiani DC (2016) Whole blood microRNAs as a prognostic classifier for acute respiratory distress syndrome 28-day mortality. *Intensive Care Med* 42(11):1824
2. Heyn H, Esteller M (2012) DNA methylation profiling in the clinic: applications and challenges. *Nat Rev Genet* 13(10):679–692
3. Pettipher R, Hansel TT, Armer R (2007) Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases. *Nat Rev Drug Discov* 6(4):313–325
4. Fingerlin TE, Murphy E, Zhang W, Peljto AL, Brown KK, Steele MP, Loyd JE, Cosgrove GP, Lynch D, Groshong S, Collard HR et al (2013) Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. *Nat Genet* 45(6):613–620
5. van der Mark VA, Ghiboub M, Marsman C, Zhao J, van Dijk R, Hiralall JK, Ho-Mok KS, Castricum Z, de Jonge WJ, Elferink RP, Paulusma CC (2017) Phospholipid flippases attenuate LPS-induced TLR4 signaling by mediating endocytic retrieval of Toll-like receptor 4. *Cell Mol Life Sci* 74(4):715–730